Physician profile
Eric Carl Downes
NPI 1710368840
$996.16
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.97 · 2020: $113 · 2021: $216 · 2022: $575.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $385.33 | 2021-2022 | |
| Tris Pharma INC | $133.08 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $131.96 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $66.70 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $63.93 | 2021-2022 | |
| Allergan, INC. | $58.47 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $36.45 | 2021-2022 | |
| Corium, LLC | $22.76 | 2022 | |
| Jazz Pharmaceuticals INC. | $22.24 | 2021 | |
| Ironshore Pharmaceuticals INC. | $20.44 | 2020 | |
| Lundbeck LLC | $14.82 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.10 | 2022 | |
| Alkermes, INC. | $13.12 | 2022 | |
| Neuronetics, INC. | $12.76 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Downes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.